Vanda Pharmaceuticals Inc.
Treatment of circadian rhythm disorders

Last updated:

Abstract:

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Status:
Grant
Type:

Utility

Filling date:

6 Jul 2021

Issue date:

29 Mar 2022